Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754074 | 0.84 | CYP19A1 (0.37) | CYP19A1EPHX1GPR35HTTNAAA | |
| SCHEMBL17752185 | 0.82 | CYP19A1 (0.42) | CYP19A1EPHX1HTTNPC1RAB9A | |
| SCHEMBL10016871 | 0.78 | CYP19A1 (0.34) | CYP19A1EPHX1 | |
| SCHEMBL9130045 | 0.77 | EPHX1 (0.38) | CYP19A1EPHX1GPR35HTTNPC1 | |
| Methane SCHEMBL28111858 | 0.76 | EPHX1 (0.44) | CYP19A1EPHX1GPR35HTTNPC1 | |
| SCHEMBL17752187 | 0.75 | HSD11B1 (0.36) | EPHX1 | |
| SCHEMBL18822970 | 0.74 | EPHX1 (0.46) | CYP19A1EPHX1GPR35HTTSMN1; SMN2 | |
| SCHEMBL16297135 | 0.74 | EPHX1 (0.46) | CYP19A1EPHX1GPR35HTTSMN1; SMN2 | |
| SCHEMBL22480 | 0.74 | EPHX1 (0.46) | CYP19A1EPHX1GPR35HTTSMN1; SMN2 | |
| SCHEMBL887989 | 0.74 | EPHX1 (0.46) | CYP19A1EPHX1GPR35HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9971241-B2 | Compound, resin, resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160139508-A1 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160139508-A1 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | AFF1, AFF2, AFF4 | CYP19A1 630/4885EPHX1 923/4885GPR35 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.